The logo of Swiss drug-maker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.The logo of Swiss drug-maker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.
Both drugs are designed to remove forms of the protein beta amyloid from the brain, sticky plaques believed to play a major role in the disease. The field of Alzheimer’s research is littered with failure and disappointment, including for several drugs in the same class, and previous efforts to prove gantenerumab’s worth.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: